Low Dose Ketamine Intra Nasal Traumatology (Ket)
Primary Purpose
Trauma
Status
Completed
Phase
Phase 2
Locations
Tunisia
Study Type
Interventional
Intervention
Ketamine
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Trauma focused on measuring Ketamine-Intranasal-Acute pain-Emergency departement
Eligibility Criteria
Inclusion Criteria:
- The study includes patients aged 18 to 80 years who presented to the ED with acute limb trauma pain with a visual analgesic scale (VAS) of 5 or more on a standard 11- point (0 to 10). An informed consent is necessary.
Exclusion Criteria:
- - Pregnancy,
- Breast-feeding,
- Altered mental status,
- Allergy to ketamine or morphine or
- Weight less than 46 kg or greater than 115 kg,
- Unstable vital signs (systolic blood pressure <90 or >180 mm Hg, pulse rate <50 or >150 beats/min, and respiration rate <10 or >30 breaths/min),
- Medical history of acute head or eye injury, seizure, intracranial hypertension, chronic pain, severre renal or hepatic insufficiency,
- Alcohol or drug abuse,
- Psychiatric illness,
- Recent (4 hours before) analgesic agent use.
Sites / Locations
- Nouira Samir
- Emergency department of university hospital Fattouma Bourguiba of Monastir
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
placebo group
Ketamine group
Arm Description
Intranasal placebo pulverisation
Intranasal ketamine pulverisation
Outcomes
Primary Outcome Measures
Number and percentage of patients who need rescue opiods in the two groups
the need for rescue opioids during ED stay
Secondary Outcome Measures
Intolerance to treatement and adverse events
Noticing any sign of intolerance due to treatement : Dizziness , Vomiting..
Percentage of patients with VAS <30 mm at discharge
percentage of patients discharged from the ED with VAS <30.
Number and percentage of patients who required non opiods analgesics
Requirement of non-opioids analgesic agents
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03233035
Brief Title
Low Dose Ketamine Intra Nasal Traumatology
Acronym
Ket
Official Title
Intranasal Ketamine for Treatment of Acute Pain in the Emergency Department : A Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
June 2019
Overall Recruitment Status
Completed
Study Start Date
January 1, 2018 (Actual)
Primary Completion Date
December 1, 2018 (Actual)
Study Completion Date
December 1, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Monastir
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To evaluate the efficacy and safety of early administration of low-dose intranasal ketamine analgesic agents in patients with moderate to severe pain in the ED in reducing the need for opioid or non opioids analgesic agents.
Detailed Description
Intranasal ketamine for treatment of acute pain in the emergency department : A randomized controlled trial
Introduction :
Pain is the most common complaint for emergency department (ED) visits [1].The provision of adequate, safe, and timely analgesia is a core component of patient care in the emergency department (ED). Ketamine is a noncompetitive Nmethyl- D-aspartate and glutamate receptor antagonist that decreases central sensitization, "wind-up" phenomena, and pain memory [2,3].
At subdissociative doses (0.1 to 0.6 mg/kg; most commonly 0.3 mg/kg) maintains potent analgesic and amnestic effects that are accompanied by preservation of protective airway reflexes, spontaneous respiration, and cardiopulmonary stability [4-6].
Intranasal route ….
Objective of the study :
To evaluate the efficacy and safety of early administration of low-dose intranasal ketamine analgesic agents in patients with moderate to severe pain in the ED in reducing the need for opioid or class III analgesic agents.
Materials and Methods :
Study design :
It is a ramdomized, prospective, double blind, controlled, multicentric trial. The study is registered with clinical.tria.gov (…….).
Study Setting and Selection of Participants :
The trial is conducted in three community teaching hospitals :
Emergency department, fattouma bourguiba university hospital, monastir, tunisia
Emergency department, sahloul university hospital, sousse, tunisia
Emergency department, farhat hached university hospital, sousse, tunisia
ED principal investigators maintain the randomization list, which is generated before the start of the study, prepare the medication, and deliver it to the treating physician in a blinded manner.
Inclusion criteria :
The study includes patients aged 18 to 80 years who presented to the ED with acute limb trauma pain with a visual analogue scale (VAS) of 5 or more on a standard 11- point (0 to 10). An informed consent is necessary.
Exclusion criteria :
Pregnancy,
Breast-feeding,
Altered mental status,
Allergy to ketamine or morphine or
Weight less than 46 kg or greater than 115 kg,
Unstable vital signs (systolic blood pressure <90 or >180 mm Hg, pulse rate <50 or >150 beats/min, and respiration rate <10 or >30 breaths/min),
Medical history of acute head or eye injury, seizure, intracranial hypertension, chronic pain, severre renal or hepatic insufficiency,
Alcohol or drug abuse,
Psychiatric illness,
Recent (4 hours before) analgesic agent use.
Protocol :
In the triage area, each patient having the inclusion criteria receives 25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril or 0.5 mL of normal saline solution in one pulverisation per nostril as a placebo according to the predetermined randomization list. None of the treating physician or nurses is aware about the medication received. In all patients included, the investigators collect vital signs ; demographic and clinical data.
Study investigators record VAS, and adverse effects at 15, 30, 60, 90, and 120 minutes.
At 30 minutes, if patients report a pain numeric rating scale score of 5 or greater and request additional pain relief, titrated morphine is administered as a rescue analgesic with a dose of 0.1 mg/Kg repeated every 3 to 5 minutes if the pain numeric rating scale score is still greater or equal to 3.
All data recorded on data collection sheets, including sex, demographics, medical history, and vital signs, were entered into SPSS (version 20.0; IBM Corp) by the research manager.
Patients's informed consent is obtained. The ethic commitee of our institution approved the study.
Endpoints :
Primary endpoints :
- Need for rescue opioids during ED stay
Secondary endpoints :
requirement of non-opioids analgesic agents.
percentage of patients discharged from the ED with VAS <30.
Safety : adverse events
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Trauma
Keywords
Ketamine-Intranasal-Acute pain-Emergency departement
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Double Blind Study
Masking
ParticipantCare ProviderInvestigator
Masking Description
Ketamine versus placebo as a double blind study
Allocation
Randomized
Enrollment
1102 (Actual)
8. Arms, Groups, and Interventions
Arm Title
placebo group
Arm Type
Placebo Comparator
Arm Description
Intranasal placebo pulverisation
Arm Title
Ketamine group
Arm Type
Active Comparator
Arm Description
Intranasal ketamine pulverisation
Intervention Type
Drug
Intervention Name(s)
Ketamine
Intervention Description
25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril is received
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
normal saline solution
Intervention Description
0.5 mL of normal saline solution as a placebo in one pulverisation per nostril
Primary Outcome Measure Information:
Title
Number and percentage of patients who need rescue opiods in the two groups
Description
the need for rescue opioids during ED stay
Time Frame
30 minutes
Secondary Outcome Measure Information:
Title
Intolerance to treatement and adverse events
Description
Noticing any sign of intolerance due to treatement : Dizziness , Vomiting..
Time Frame
30 minutes and at 120 minutes
Title
Percentage of patients with VAS <30 mm at discharge
Description
percentage of patients discharged from the ED with VAS <30.
Time Frame
120 minutes
Title
Number and percentage of patients who required non opiods analgesics
Description
Requirement of non-opioids analgesic agents
Time Frame
30 minutes
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
The study includes patients aged 18 to 80 years who presented to the ED with acute limb trauma pain with a visual analgesic scale (VAS) of 5 or more on a standard 11- point (0 to 10). An informed consent is necessary.
Exclusion Criteria:
- Pregnancy,
Breast-feeding,
Altered mental status,
Allergy to ketamine or morphine or
Weight less than 46 kg or greater than 115 kg,
Unstable vital signs (systolic blood pressure <90 or >180 mm Hg, pulse rate <50 or >150 beats/min, and respiration rate <10 or >30 breaths/min),
Medical history of acute head or eye injury, seizure, intracranial hypertension, chronic pain, severre renal or hepatic insufficiency,
Alcohol or drug abuse,
Psychiatric illness,
Recent (4 hours before) analgesic agent use.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nouira Semir, Professor
Organizational Affiliation
university Hospital of Monastir
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nouira Samir
City
Monastir
State/Province
Emergency Department Monastir, Tunisia 5000
ZIP/Postal Code
5000
Country
Tunisia
Facility Name
Emergency department of university hospital Fattouma Bourguiba of Monastir
City
Monastir
ZIP/Postal Code
5000
Country
Tunisia
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Low Dose Ketamine Intra Nasal Traumatology
We'll reach out to this number within 24 hrs